Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
IGF-1 LR3 vs MK-677 (Ibutamoren)
An educational, source-based comparison of IGF-1 LR3 and MK-677 (Ibutamoren) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
IGF-1 LR3 vs MK-677 (Ibutamoren) — Key differences
- Class: IGF-1 LR3 is classified as Growth Factor, while MK-677 (Ibutamoren) is Growth Hormone Axis · Small Molecule.
- Primary research focus: IGF-1 LR3 — muscle protein synthesis (preclinical); MK-677 (Ibutamoren) — gh/igf-1 elevation in adults.
- Tag: Growth · Recovery vs Growth hormone · Oral.